# Nicholas D. James

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nicholas-d-james/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,476 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 75 |
| i10-index | 253 |
| Last Known Institution | Royal Marsden NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5022378006 |
| ORCID iD | https://orcid.org/0000-0002-7314-8204 |
| Works | 615 |

## Researcher papers

- [Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer](https://scholariq.org/papers/docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate/)
- [Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial](https://scholariq.org/papers/addition-of-docetaxel-zoledronic-acid-or-both-to-first-line-long-term-hormone/)
- [Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy](https://scholariq.org/papers/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy/)
- [Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial](https://scholariq.org/papers/radiotherapy-to-the-primary-tumour-for-newly-diagnosed-metastatic-prostate/)
- [The Lancet Commission on prostate cancer: planning for the surge in cases](https://scholariq.org/papers/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases/)
- [Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial](https://scholariq.org/papers/timing-of-radiotherapy-after-radical-prostatectomy-radicals-rt-a-randomised/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review](https://scholariq.org/papers/critical-analysis-of-bladder-sparing-with-trimodal-therapy-in-muscle-invasive/)
- [EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†](https://scholariq.org/papers/eau-esmo-consensus-statements-on-the-management-of-advanced-and-variant-bladder/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)

## Researcher university

- [Royal Marsden NHS Foundation Trust](https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.